cloaked, I do think Bavi can be significantly useful, but prolongation of life by 3-4 months against end-stage could be argued in some circle to not be a cost-effective end of life treatment. For instance, in that last two or three months of life simply getting into a car and going to a doctor's office for any treatment could be grueling. That aside, I think asking a agent with more of action similar to Bavi to significantly reduce large solid tumor load is a bit of a pipe dream. As said repeatedly, it will be of the utmost interest just to see what Bavi does to micro-metastases, for instance, and we will get that information. The "spin-off' knowledge gained from trials such as these can sometimes be as/more important than the stated goal or endpoint. And again as previously stated, I think you have to be a cancer surgeon to appreciate some of these concepts. The idea of an immunologic approach to cancer therapy has been around since before the early seventies when I came into contact with it while in surgical training. That was almost a half-century ago. The gains in I-O for solid tumors have been inordinately costly and relatively low-yield. It does sound good though. That is a part of what I classify a pipe dream.
Market Data 
Markets 
AI
